Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 22, 2024 at 02:35 am IST
Share
Nevro Corp. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 116.18 million compared to USD 113.84 million a year ago. Net loss was USD 8.98 million compared to USD 19.19 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.54 a year ago. Diluted loss per share from continuing operations was USD 0.25 compared to USD 0.54 a year ago.
For the full year, sales was USD 425.17 million compared to USD 406.37 million a year ago. Net loss was USD 92.21 million compared to net income of USD 3 million a year ago. Basic loss per share from continuing operations was USD 2.56 compared to basic earnings per share from continuing operations of USD 0.08 a year ago. Diluted loss per share from continuing operations was USD 2.56 compared to diluted earnings per share from continuing operations of USD 0.08 a year ago.
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.